Should patients who have suffered an acute myocardial infarction be treated with clopidogrel long-term to prevent further cardiac events?
Patients with suspected myocardial infarction without ST segment elevation were eligible for the CURE Study and accounted for approximately 25% of the patients enrolled. There was a significant reduction in the primary outcome of CV death, MI or stroke with clopidogrel compared to placebo in this group of patients. The question of whether patients with acute myocardial infarction with ST segment elevation who are candidates for reperfusion therapy will benefit from clopidogrel was not an objective of the CURE trial.
